MetrioPharm has released its annual report 2021. The company has provided an overview of the previous year’s achievements, the current state, and gives an outlook on the future business strategy. Thomas Christély, MetrioPharm’s CEO since last October, mentions in his preface that the company was able to increase its equity by a total of CHF 27.5 million in 2021.
Metriopharm’s ‘iMPact’ project was awarded a €7.9 million grant from the COVID-19 work programme from Horizon Europe in November of 2021, to clinically validate MP1032, an early intervention treatment against mild-to-moderate COVID-19. In this project, MetrioPharm has joined forces with three consortium partners, ImmunoLogik, Catalyze, and PHOX Consulting e.U. Our Partner Catalyze spoke with Dr. Wolfgang Brysch, Chief Scientific Officer and Chief Medical Officer of Metriopharm, to hear more about their mission, the iMPact project. Here is the article:
A conversation with Dr. Petra Schulz Discussing MetrioPharm’s Phase II Clinical Study in COVID-19
MetrioPharm is currently preparing a clinical trial of its lead compound MP1032 in COVID-19. How do you conduct study preparations under pandemic conditions?
The landscape has changed...
A Current Publication by Dr. Wolfgang Brysch On the Prevention and Treatment of Covid-19
Which are the factors that determine the course of a Covid-19 infection? Whether patients develop symptoms, whether they fall seriously ill, whether they need to be treated in a hospital?
A decisive factor seems to be the age of the patient...
Six questions and answers by MetrioPharm CEO Dr. Wolfgang Brysch on the compound MP1032 in COVID-19
Is MetrioPharm developing a compound for the treatment of COVID-19?
Wolfgang Brysch: We are developing our lead compound MP1032 for the treatment of chronic inflammatory diseases, with the molecule targeting oxidative stress. Oxidative stress also plays a central role in COVID-19 disease...
Background Discussion on MetrioPharm’s Preclinical COPD Study
MetrioPharm recently completed a study in a new preclinical model. What did this model look like?
Dr. Sara Schumann: For this initial study we chose an ex vivo model, in which the tests are performed on an isolated heart and lung system...
Article from the Frankfurter Allgemeine Zeitung from December 24, 19:
Who Wants To Live Forever?
2019 was the year of spectacular news, generated from the field of aging research. Supposedly, scientists had succeeded in slowing down the aging process, stopping it, even reversing it. As if life was an hourglass and we had learned how to stop time from running out by popping a pill, or even how to reverse the life flow.
A Conversation About MetrioPharm AG’s Phase II Clinical Trial
MetrioPharm AG has just published Top Line Data for the Phase II clinical trial in psoriasis. Was the study a success?
Wolfgang Brysch: Yes, the study was clearly a success. We had a number of specific questions and were able to answer most of them...
A Conversation With the New MetrioPharm CFO Sven Zimmermann
You have been working in the life science and healthcare sector for more than fifteen years. What makes this work so appealing?
The sector has its own special challenges. On the one hand, the costs for drug development are significant and the development itself is highly regulated...